Josh Lingo

PhD. Candidate - Cancer Biology | My tweets are my own

[Josh Lingo @LingointheLab]

Really proud to work with such a great group! Here’s our latest commentary on therapy resistance in MPNSTs:

[Oncotarget @Oncotarget]

#PaperSpotlight: A new mini #review was #published on September 30, entitled, "Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors."

#PressRelease ⬇️
https://t.co/oeDWDAu0fA

#cancer #MPNST #oncology #tumors #oa #press

[Amira Zaher @Amira_A_Zaher]

Grateful for the opportunity to contribute to radiation injury model development! Just published a pilot study on the utility of single lung irradiation in the detection of changes in Fe metabolism during radiation injury.
https://t.co/J4luuXkc1W

[Israel Jacob Wipf @israelwipf]

Monday microscopy

Fruit fly egg chambers visualized by fluorescence microscopy. Colored in yellow is actin, a protein component of the cytoskeleton (which among other things gives the cell its structure). And in blue is DNA, stored in the cell’s nucleus.

#microscopy #science

[Josh Lingo @LingointheLab]

I’m so honored and excited to keep working toward understanding how plasma cells shape the sarcoma microenvironment!!

[Brian Van Tine @bvantine1]

CDK4/6-MEK inhibition in MPNSTs causes plasma cell infiltration, sensitization to PD-L1 blockade, and tumor regression https://t.co/y5cbrRMwpu

More progress on MPNSTs #sarcoma @CCR_AACR

[CrozrX @CrozrX]

Preclinical findings provide strong rationale for clinical translation of CDK4/6▪︎MEK▪︎ICB 🎯 therapies in #MPNST as they may yield sustained antitumor responses and improved patient outcomes.
@LingointheLab

[UIowaNeuroPharm @IowaNeuroPharm]

Joshua Lingo, Graduate Research Assistant in the Quelle lab, has received an NIH NRSA F31 Diversity Award.
Congratulations Joshua! 🎉

[Josh Lingo @LingointheLab]

@Amira_A_Zaher

[Josh Lingo @LingointheLab]

@Amira_A_Zaher Just submitted last week where the website logged you out every 5 minutes regardless of activity unless you clocked a button 🙃

[Josh Lingo @LingointheLab]

Cheers to being a fully self-funded grad student cheers 🥂

[Josh Lingo @LingointheLab]

Time to teach my first undergraduate lecture!

[Josh Lingo @LingointheLab]

About to give my final seminar of my T32 appointment on harnessing host immunity to combat MPNSTs

[Josh Lingo @LingointheLab]

Incredible talk from @Moran_Lab on the role of the androgen receptor in prostate cancer and the efficacy of immunotherapy 🤯

[Josh Lingo @LingointheLab]

So happy to have presented my recent work on immunotherapy and MPNSTs at #AACRtii22

[Josh Lingo @LingointheLab]

Boston here I come! #AACRtii22 🧬🧪

[Josh Lingo @LingointheLab]

Incredibly excited to be attending my first national conference! Can’t wait to learn about cutting edge in tumor immunology 🧬🔬🧪 #AACRtii22

[Josh Lingo @LingointheLab]

Just submitted my first fellowship of my academic career!!’ Fingers crossed 🤞🏼 #sarcoma #immunotherapy #CancerResearch